Abstract: The present disclosure relates to a method of producing lactic acid bacteria dual-coated with protein and polysaccharide by using a protein hydrolysate, and lactic acid bacteria having a dual coating, produced by the method. The lactic acid bacteria having a dual coating of protein and polysaccharide, produced according to the present disclosure, have very excellent dry-freezing viability, acid resistance and bile resistance. Accordingly, the lactic acid bacteria having a dual coating of protein and polysaccharide according to the present disclosure will be very useful for the production of fermented milk, processed milk, fermented soy products, processed foods, functional beverages, functional foods, common foods, etc.
Abstract: This invention relates to botulinum toxin formulations that are stabilized without the use of any proteinaceous excipients. The invention also relates to methods of preparing and using such botulinum toxin formulations.
Type:
Grant
Filed:
May 18, 2021
Date of Patent:
February 27, 2024
Assignee:
REVANCE THERAPEUTICS, INC.
Inventors:
Stewart A. Thompson, Curtis L. Ruegg, Jacob M. Waugh
Abstract: The present disclosure relates to compositions and methods for inhibiting bacterial aggregation, and in particular, to compositions and methods that inhibit autotransporter-mediated bacterial aggregation or attachment. Described herein are autotransporter binding molecules such as antibodies and antigen binding fragments thereof. The autotransporter binding molecules block self-association between autotransporters and autotransporter-mediated surface attachment.
Type:
Grant
Filed:
February 22, 2021
Date of Patent:
February 13, 2024
Assignees:
La Trobe University, The University of Queensland
Inventors:
Begona Heras, Jason Paxman, Mark Schembri, Alvin Lo
Abstract: The present invention features compositions comprising an anti-amyloid antibody and methods of treating microbial infection and treating or preventing microbial biofilms using the composition.
Type:
Grant
Filed:
May 24, 2019
Date of Patent:
February 13, 2024
Assignees:
Temple University—Of The Commonwealth System of Higher Education, LANKENAU INSTITUTE OF MEDICAL RESEARCH
Abstract: The present invention relates to a host cell, which comprises under the control of a heterologous promoter a polynucleotide comprising a nucleotide sequence encoding a polypeptide capable of synthesizing a polysaccharide consisting of a dimeric repeating unit as well as to a vaccine composition comprising such host cell. Furthermore, either such host cell or a polypeptide expressed by such host cell is used for the production of a polysaccharide consisting of a dimeric repeating unit which may be used as a glycoconjugate vaccine.
Abstract: The present invention provides a method of producing a polysaccharide-protein conjugate with capsular polysaccharide from Streptococcus pneumoniae serotype 19F conjugated to a carrier protein. The method includes a prolonged incubation step prior to filtration to remove free polysaccharide.
Type:
Grant
Filed:
December 7, 2021
Date of Patent:
January 30, 2024
Assignee:
Merck Sharp & Dohme LLC
Inventors:
Michael Albert Winters, John E. MacNair
Abstract: In various embodiments devices and methods for the detection and/or quantification of clinically relevant pathogens (e.g., bacteria, fungi, viruses, etc.) are provided. In certain embodiments the device comprises a lateral-flow assay that detects the bacterium at a concentration of less than about 6×106 cells/mL, less than about 3×106 cells/ml, less than about 1×106 CFU/mL, or less than about 50 ?g/mL. In certain embodiments the device comprises an aqueous two-phase system (ATPS) comprising a mixed phase solution that separates into a first phase solution and a second phase solution; and a lateral-flow assay (LFA). In certain embodiments the device comprises a flow-through system comprising a concentration component comprising an aqueous two-phase system (ATPS) comprising a mixed phase solution that separates into a first phase solution and a second phase solution; and a detection component disposed beneath said concentration component.
Type:
Grant
Filed:
February 16, 2022
Date of Patent:
January 30, 2024
Assignee:
The Regents of the University of California
Inventors:
Daniel Takashi Kamei, Yin To Chiu, Benjamin Ming Wu, Garrett L. Mosley
Abstract: In certain embodiments, the present invention provides a poultry vaccine comprising an antigenic protein comprising a PlcC protein unit that is operably linked to a peptide linker that is operably linked to a NetB protein unit, where the vaccine is effective in stimulating a protective cellular and/or humoral immune response to C. perfringens. Methods are also provided for making the vaccine and for vaccinating poultry by administering such a vaccine.
Type:
Grant
Filed:
December 27, 2022
Date of Patent:
January 2, 2024
Assignee:
ARIZONA BOARD OF REGENTS ON BEHALF ARIZONA STATE UNIVERSITY
Inventors:
Kenneth Roland, Andrew Diamos, Hugh Mason
Abstract: Combination therapeutics for the treatment of cancer include the use of immune effector cells, IL-15 based superagonists and one or more immunotherapeutic agents such as Bacillus Calmette-Guerin (BCG).
Abstract: The present invention relates to compositions, methods, and kits for predicting a subject's response to a CAR T cell therapy, by analyzing the intestinal microbiome of the subject. The present disclosure also provides a method of detecting patients at risk for a poor response to CAR T cell therapy by measuring the level of the presently disclosed bacteria or bacterial genes in the microflora or microbiome of a patient receiving or considered for CAR T cell therapy. The present disclosure further provides therapeutic compositions and methods for treating a subject having a cancer, by improving the subject's response to a CAR T cell therapy.
Type:
Grant
Filed:
April 13, 2021
Date of Patent:
January 2, 2024
Assignee:
MEMORIAL SLOAN-KETTERING CANCER CENTER
Inventors:
Melody Smith, Marcel van den Brink, Eric Pamer, Eric Littmann
Abstract: The invention features probiotic bacteria expressing Clostridium difficile SlpA, or fragment thereof, and its use for the treatment or prevention of Clostridium difficile infection and gut colonization.
Type:
Grant
Filed:
January 22, 2021
Date of Patent:
December 12, 2023
Assignees:
ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA, The United States Government as represented by the Department of Veterans Affairs
Inventors:
Gayatri Vedantam, Virinchipuram K. Viswanathan, Michael Mallozzi
Abstract: The present description relates to chimeric bacteriophage lysins useful for the identification and/or reduction of staphylococcal populations. For example, a chimeric bacteriophage lysin was engineered and shown to effectively kill all strains of staphylococci tested including antibiotic resistant methicillin-resistant S. Aureus and VISA.
Type:
Grant
Filed:
May 24, 2021
Date of Patent:
November 28, 2023
Assignee:
The Rockefeller University
Inventors:
Vincent A Fischetti, Anu Daniel, Chad Euler
Abstract: The present invention provides, among other things, compositions and methods relating to detection and/or treatment cancer (e.g., one or more tumors) that expresses Neuropilin 1 (NRP1). The present invention provides methods of treating cancer that include administering a chlorotoxin agent to a subject (e.g., to a subject suffering from or susceptible to the cancer which may, in some embodiments, be a cancer that expresses NRP1). In some embodiments, a chlorotoxin agent for use in accordance with the present invention can be or comprise a chlorotoxin polypeptide and a payload moiety (e.g., as a covalent conjugate).
Type:
Grant
Filed:
September 14, 2018
Date of Patent:
November 28, 2023
Assignee:
Eisai Inc.
Inventors:
Sharon McGonigle, Utpal Majumder, Maarten H. D. Postema
Abstract: The present invention relates to a live attenuated Bordetella pertussis vaccine which is deficient for tracheal cytotoxin (TCT), pertussis toxin (PTX), and dermonecrotic toxin (DNT) for prophylaxis or treatment of an allergen-driven airway pathology.
Type:
Grant
Filed:
August 2, 2021
Date of Patent:
November 21, 2023
Inventors:
Camille Locht, Bernard Mahon, Heather Kavanagh
Abstract: The present invention relates to a vaccine comprising a nucleic acid construct such as a DNA construct especially a nucleic acid construct comprising sequences encoding invariant chain operatively linked to antigenic protein or peptide encoding sequences. The present vaccine stimulates an enhanced immune response.
Type:
Grant
Filed:
October 18, 2021
Date of Patent:
November 14, 2023
Assignee:
UNIVERSITY OF COPENHAGEN
Inventors:
Peter Johannes Holst, Cyrielle Elyette Fougeroux
Abstract: The present disclosure relates to immunogenic polypeptides, immunogenic compositions and vaccine compositions and use thereof for immunization of mammals susceptible to Streptococcus suis infection. The disclosure also relates to methods for preparing, formulating and administrating such compositions.
Type:
Grant
Filed:
October 22, 2021
Date of Patent:
November 14, 2023
Assignee:
INTERVACC AB
Inventors:
Bengt Guss, Lars Frykberg, Margareta Flock, Jan-Ingmar Flock, Karl Olov Zachrisson
Abstract: The invention provides methods and compositions for treating fibromyalgia (FM) and chronic fatigue syndrome (CFS) in an individual. The methods provided herein entail administering a composition comprising an isolated Mycobacterium or antigenic fragments derived therefrom. Also provided herein are methods for assessing alleviation of symptoms and/or alteration of immune system functioning following administration of a composition comprising an isolated Mycobacterium or antigenic fragments derived therefrom.
Abstract: Disclosed is an in vitro method for assessing whether a human subject has periodontitis. The method comprises detecting, in a sample of saliva from said subject, the concentrations of the proteins Hepatocyte Growth Factor (HGF) and Matrix Metalloproteinase 8 (MMP-8). Based on the concentrations determined, and adding age, and possibly other demographic markers such as sex and/or BMI, a testing value reflecting the joint concentrations is determined for said proteins, in combination with one or more demographic markers. The testing value is compared with a threshold value. The threshold reflects in the same manner the joint concentrations and the age, and possibly other demographic markers, as associated with periodontitis and may be seen as an upper limit of testing values as seen in a population of subjects without periodontitis. Thereby a testing value at or above the threshold value is indicative for periodontitis in said subject.
Type:
Grant
Filed:
May 24, 2018
Date of Patent:
September 26, 2023
Assignee:
KONINKLIJKE PHILIPS N.V.
Inventors:
Bart Jacob Bakker, Marinus Karel Johannes De Jager, Amir Hussein Rmaile, Philip Preshaw, John Taylor
Abstract: The object of the invention is to provide a composition for enhancing an immune checkpoint blockade therapy. A composition for enhancing an immune checkpoint blockade therapy, which contains an exopolysaccharide of a lactic acid bacterium is provided. Preferred examples of the lactic acid bacterium include Lactobacillus bacteria (especially Lactobacillus delbrueckii subsp. bulgaricus OLL1073 R-1).
Abstract: The present disclosure relates to aptamers, polynucleotides, and nuclei acid molecules, which include a polynucleotide sequence capable of specifically binding polypeptides participating in M. hyopneumoniae infection. Also provided are methods of using nucleic acid molecules, polynucleotides and synthetic antibodies directed there against for detection, treating and neutralization of M. hyopneumoniae infection.
Type:
Grant
Filed:
March 3, 2022
Date of Patent:
September 12, 2023
Assignee:
AEROVIRUS TECHNOLOGIES INC.
Inventors:
Norman J Marchand, Thomas G Caltagirone, Albert Liao